Reuters logo
BRIEF-Paradigm Biopharmaceuticals completes Phase 2A clinical trial in bone marrow lesions
November 13, 2017 / 10:34 PM / 8 days ago

BRIEF-Paradigm Biopharmaceuticals completes Phase 2A clinical trial in bone marrow lesions

Nov 14 (Reuters) - Paradigm Biopharmaceuticals Ltd

* ‍Successfully completes Phase 2A clinical trial in bone marrow lesions

* Phase 2A clinical trial in bone marrow lesions (bone bruising) met its primary endpoint of safety & tolerability​

* ‍Secondary endpoint was met and showed a statistically significant reduction in bone marrow lesion volume​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below